In this study the effectiveness of degarelix, a long acting GnRH antagonist administered in a unique administration of 20 mg the first day of menstrual cycle, to prevent ovarian hyperstimulation syndrome (OHSS) in PCOS women at risk to develop OHSS.
Women with PCOS are at risk to develop OHSS when stimulated with gonadotrophins for IVF. For this reason in this study the degarelix was tested in order to minimize the risk of OHSS as well as to improve the pregnancy rate in these patients. The use of long acting GnRH antagonist promotes a deep suppression of LH and consequently the activity of theca cells, which secrete androgens (the precursors of estradiol), and consequently the levels of estradiol remains low. Comparing the long acting GnRH antagonist at the first day of cycle with a flexible GnRH antagonist protocol in a group of patients with PCOS will be useful in order to establish the best way to perform controlled hyperstimulation in IVF cycles and minimize the risk of OHSS.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
80
20 mg of degarelix the first day of menstrual cycle before starting with gonadotrophins administration
0.25mg of cetrorelix during treatment with gonadotrophins when estradiol levels were \>300pg/ml
Cerm-Hungaria
Rome, Italy
PREGNANCY RATE
number of ongoing pregnancy obtained in the group
Time frame: 6 MONTHS
ovarian hyperstimulation syndrome rate
incidence of ovarian hyperstimulation syndrome in the groups
Time frame: 6 MONTHS
implantation rate
number of implanted embryos divided for the number of transferred embryos
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.